Combining Liposomal Honokiol with Cisplatin for Lung Cancer Treatment
Author Information
Author(s): Jiang Qi-qi, Fan Lin-yu, Yang Guang-li, Guo Wen-Hao, Hou Wen-li, Chen Li-juan, Wei Yu-quan
Primary Institution: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University
Hypothesis
Does liposomal honokiol have antitumor activity against human lung cancer and can it enhance the effects of cisplatin?
Conclusion
Liposomal honokiol alone has antitumor activity against lung cancer, and its combination with cisplatin enhances this effect.
Supporting Evidence
- Liposomal honokiol alone effectively suppressed tumor growth.
- The combination of honokiol and cisplatin significantly increased life span.
- More apoptotic cells were observed in tumors treated with the combination therapy.
Takeaway
This study found that a special form of honokiol can help fight lung cancer better when used with another drug called cisplatin.
Methodology
Mice with lung cancer were treated with liposomal honokiol, cisplatin, or a combination, and tumor growth and survival were measured.
Participant Demographics
Human A549 lung cancer-bearing nude mice
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website